Evidence map›Paper›PMID 38349159›Full record

ArticleAntimicrobial agents and chemotherapy2024

Effect of the aggregated protein dye YAT2150 on

Lucía Román-Álamo, Yunuen Avalos-Padilla, Inés Bouzón-Arnáiz, Valentín Iglesias, Jorge Fernández-Lajo, Juan M Monteiro, Luis Rivas, Roser Fisa, Cristina Riera, David Andreu and 5 more

Open access · hybridAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Overexpression inFrontiers in cellular and infection microbiology · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Lucía Román-ÁlamoBarcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Yunuen Avalos-PadillaBarcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Inés Bouzón-ArnáizBarcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Valentín IglesiasBarcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Jorge Fernández-LajoCentro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Juan M MonteiroCentro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Luis RivasCentro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Roser FisaSection of Parasitology Department of Biology, Health and Environment, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.
Cristina RieraSection of Parasitology Department of Biology, Health and Environment, Faculty of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain.
David AndreuDepartment of Medicine and Life Sciences, Barcelona Biomedical Research Park, Pompeu Fabra University, Barcelona, Spain.
Carlos Pintado-GrimaInstitut de Biotecnologia i de Biomedicina (IBB) and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Salvador VenturaInstitut de Biotecnologia i de Biomedicina (IBB) and Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain.
Elsa M ArceLaboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
Diego Muñoz-TorreroLaboratory of Medicinal Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain.
Xavier Fernàndez-BusquetsBarcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0002-4622-9631
Institute for Bioengineering of Catalonia · ESUniversitat de Barcelona · ESConsejo Superior de Investigaciones Científicas · ESUniversitat Autònoma de Barcelona · ESUniversitat Pompeu Fabra · ES

Funding

Fundació la Marató de TV3 (Fundació la Marató) Ref. 201811Generalitat de Catalunya (Government of Catalonia) 2021-SGR-00357Generalitat de Catalunya (Government of Catalonia) 2021-SGR-00635'la Caixa' Foundation ('la Caixa') HR17-00409MEC | Consejo Superior de Investigaciones Científicas (CSIC) PIE 201620E038Ministerio de Ciencia e Innovación (MCIN) AGL2017-84097-C2-2-RMinisterio de Ciencia e Innovación (MCIN) PID2020-118127RB-I00Ministerio de Ciencia e Innovación (MCIN) PID2021-128325OB-I00Ministerio de Ciencia e Innovación (MCIN) RD16/0027/0010
6 · The paper itself

Abstract

The problems associated with the drugs currently used to treat leishmaniasis, including resistance, toxicity, and the high cost of some formulations, call for the urgent identification of new therapeutic agents with novel modes of action. The aggregated protein dye YAT2150 has been found to be a potent antileishmanial compound, with a half-maximal inhibitory concentration (IC

Indexed as

Antiprotozoal AgentsLeishmania infantumLeishmaniasisParasitesAnimalsEndothelial CellsHumansAntiprotozoal Agentsantileishmanial drugsLeishmaniaprotein aggregationYAT2150

Identifiers

PMID38349159
PMCPMC10916400
OpenAlexW4391777456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.